Wedbush lowered the firm’s price target on Vera Therapeutics (VERA) to $26 from $34 and keeps a Neutral rating on the shares. The firm notes that the Q1 financial results update was uneventful. However, Wedbush highlights the ORIGIN 3 data remains on track for a Q2 2025 readout and represents one of the most meaningful near-term catalyst for the shares. Assuming positive ORIGIN 3 data, management plans to submit an atacicept BLA by Q4 2025, which would setup a late 2026 launch. Following the update, the firm is shifting its atacicept launch out to Q4 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics Advances Atacicept in Key Trials
- Vera Therapeutics: Strong Financials and Promising Clinical Developments Support Buy Rating
- Vera Therapeutics reports Q1 EPS (81c), consensus (78c)
- Vera Therapeutics assumed with a Buy at H.C. Wainwright
- Positive Outlook for Vera Therapeutics: Buy Rating on Atacicept’s Potential in IgA Nephropathy